Targeting the P2X7 receptor in rheumatoid arthritis: Biological rationale for P2X7 antagonism

Clinical and Experimental Rheumatology

Volumn 32, Issue 6, 2014, Pages 878-882

  McInnes, Iain B ^a   Cruwys, Simon ^b   Bowers, Keith ^b   Braddock, Martin ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

AZD9056; Inflammation; Ion channels; P2X7 antagonism; Rheumatoid arthritis

Indexed keywords

ADENOSINE TRIPHOSPHATE; AZD 9056; BENZOYL BENZOYL ADENOSINE TRIPHOSPHATE; INTERLEUKIN 1; INTERLEUKIN 18; LIPOPOLYSACCHARIDE; PURINERGIC P2X7 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; 3'-O-(4-BENZOYL)BENZOYLADENOSINE 5'-TRIPHOSPHATE; ANTIINFLAMMATORY AGENT; AUTACOID; INTERLEUKIN 18 PROTEIN, HUMAN; PURINERGIC P2X RECEPTOR ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG ANTAGONISM; ENZYME ACTIVATION; ENZYME INHIBITION; EX VIVO STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RAT; RHEUMATOID ARTHRITIS; ANALOGS AND DERIVATIVES; ANIMAL; ARTHRITIS, RHEUMATOID; CELL CULTURE; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; SIGNAL TRANSDUCTION; SYNOVIUM; TIME;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, RHEUMATOID; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-1; INTERLEUKIN-18; LIPOPOLYSACCHARIDES; MOLECULAR TARGETED THERAPY; MONOCYTES; PURINERGIC P2X RECEPTOR ANTAGONISTS; RATS; RECEPTORS, PURINERGIC P2X7; SIGNAL TRANSDUCTION; SYNOVIAL MEMBRANE; TIME FACTORS;

EID: 84919494116     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. KLARESKOG L, CATRINA AI, PAGET S: Rheumatoid arthritis. Lancet 2009; 373: 659-72.
2. GABRIEL SE: Cardiovascular morbidity and mortality in rheumatoid arthritis. Am J Med 2008; 121: S9-14.
3. SATTAR N, McINNES IB: Vascular comorbidity in rheumatoid arthritis: potential mechanisms and solutions. Curr Opin Rheumatol 2005; 17: 286-92.
4. BRENNAN FM, McINNES IB: Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 2008; 118: 3537-45.
5. STRAND V, KIMBERLY R, ISAACS JD: Biologic therapies in rheumatology: lessons learned, future directions. Nat Rev Drug Discov 2007; 6: 75-92.
6. van VOLLENHOVEN RF: Treatment of rheumatoid arthritis: state of the art 2009. Nat Rev Rheumatol 2009; 5: 531-41.
7. HOGAN PG, LEWIS RS, RAO A: Molecular basis of calcium signaling in lymphocytes: STIM and ORAI. Annu Rev Immunol 2010; 28: 491-533.
8. HAN J, KANG D: TRESK channel as a potential target to treat T-cell mediated immune dysfunction. Biochem Biophys Res Commun 2009; 390: 1102-5.
9. v channels and AHNAK1 in T cells: the beauty and the beast. Immunol Rev 2009; 231: 257-64.
10. CAHALAN MD, CHANDY KG: The functional network of ion channels in T lymphocytes. Immunol Rev 2009; 231 :59-87.
11. FESKE S, PICARD C, FISCHER A: Immunodeficiency due to mutations in ORAI1 and STIM1. Clin Immunol 2010; 135: 169-82.
12. 7 receptor and its role in innate immunity. Tissue Antigens 2011; 78: 321-32.
13. 7 receptors in bone. Purinergic Signal 2009; 5: 205-21.
14. ROSENTHAL AK, GOHR CM, MITTONFITZGERALD E, LUTZ MK, DUBYAK GR, RYAN LM: The progressive ankylosis gene product ANK regulates extracellular ATP levels in primary articular chondrocytes. Arthritis Res Ther 2013; 15: R154.
15. 7 receptor-inflammasome complex has a role in modulating the inflammatory response in primary Sjögren's syndrome. J Intern Med 2013; 274: 480.
16. 7 receptor in the pathogenesis of primary Sjögren's syndrome. Arthritis Res Ther 2013; 15: R71.
17. 7 and the inflammasome. Trends Pharmacol Sci 2007; 28: 465-72.
18. 7 receptor. Crit Rev Immunol 2006; 26: 499-513.
19. DINARELLO CA: Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009; 27: 519-50.
20. MARIATHASAN S, WEISS DS, NEWTON K et al.: Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 2006; 440: 228-32.
21. GABAY C, McINNES IB: The biological and clinical importance of the 'new generation' cytokines in rheumatic diseases. Arthritis Res Ther 2009; 11: 230.
22. GRACIE JA, FORSEY RJ, CHAN WL et al.: A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Invest 1999; 104: 1393-401.
23. DAYER JM: The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis. Rheumatology (Oxford) 2003; 42(Suppl. 2): ii3-10.
24. World Intellectual Property Organization: (WO/2004/074224) Adamantane derivatives, processes for their preparation and pharmaceutical composition containing them. Available at: http://www.wipo.int/pctdb/en/wo.jsp?wo=2004074224&IA=SE2004000227&DISPLAY=DESC.
25. 7 receptor. From lead identification to drug development. J Med Chem 2009; 52: 3123-41.
26. 7 receptors. J Mol Med 2008; 86: 937-49.
27. LIEW FY, PITMAN NI, McINNES IB: Diseaseassociated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol 2010; 10: 103-10.
28. 7 antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine. Ann Rheum Dis 2012; 71: 1630-5.